Myovant Sciences Ltd.

General Information

We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders. Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist. We are advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer.

Employees: 9
Founded: 2016
Contact Information
Address Clarendon House 2 Church Street, Hamilton HM 11, Bermuda
Phone Number +1 (441) 824-8101
Web Address
View Prospectus: Myovant Sciences Ltd.
Financial Information
Market Cap $903.4mil
Revenues $0.0 mil (last 12 months)
Net Income $-20.6 mil (last 12 months)
IPO Profile
Symbol MYOV
Exchange NYSE
Shares (millions): 14.5
Price range $15.00 - $15.00
Est. $ Volume $217.5 mil
Manager / Joint Managers Citigroup/ Cowen and Company/ Evercore ISI/ Barclays
CO-Managers JMP Securities/ Baird
Expected To Trade: 10/27/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change